Boehringer Ingelheim's Breakthrough Lung Cancer Drug Wins Global Approval

Boehringer Ingelheim has developed a new drug for patients with a specific genetic mutation in non-small cell lung cancer. The treatment offers greater efficacy and improves quality of life for those affected. Regulatory approvals have already been secured in the U.S., China, and Japan. The drug’s development began eight years ago at the company’s research site in Vienna. An interdisciplinary team led the project, which moved faster than the typical 15-year timeline for drug development. Around 40,000 people worldwide receive this diagnosis annually, including many women and non-smokers.

Boehringer Ingelheim’s Regional Center Vienna oversees clinical trials across more than 30 countries. The company employs roughly 500 cancer researchers in Austria and invests about 300 million euros annually in research and development. Over the past decade, its total investment in Austria has exceeded one billion euros.

A new office building is currently under construction in Vienna-Meidling. The company also plans to launch a drug for idiopathic pulmonary fibrosis later this year, with three additional oncology treatments expected by 2028. The FDA approved the drug in August 2025, followed shortly by China and Japan. It is now available to patients in these markets. The company’s continued investment and pipeline suggest further advancements in oncology and respiratory treatments.